biotech / news / / South China Morning Post
Hong Kong is home to more than 260 listed healthcare and biotech companies with a combined market capitalisation of over HK$4.8 trillion (US$613 billion) The city government’s Innovation Technology Commission currently offers more than 50 funding schemes.
The Greater Bay Area International Clinical Trial Institute was established in 2024 for cross-border clinical trials.
KEY POINTS
- Hong Kong's '1+' mechanism since 2023 allows local clinical data to expedite new drug registration.
- A new Hong Kong Centre for Medical Products Regulation will unify oversight of all medicines and devices by year-end.
- Tigermed exceeded enrolment targets for hepatitis B clinical trials in Hong Kong ahead of schedule in 2024.
- OASES partnerships brought 30 life and health tech firms, including four top global pharmaceutical companies, to Hong Kong.
COMPANIES
Summarized by Newsio from South China Morning Post. How we summarize →